Gap19: Selective Connexin 43 Hemichannel Blocker for Neuroprotection and Immune Modulation

Executive Summary: Gap19 is a synthetic peptide derived from the intracellular cytoplasmic loop of connexin 43 (Cx43), acting as a highly selective hemichannel inhibitor without disrupting gap junction communication (APExBIO). It blocks Cx43 hemichannels with an IC₅₀ of ~50 μM in vitro and demonstrates neuroprotection in mouse models of cerebral ischemia at 300 μg/kg intracerebroventricularly. Gap19 suppresses ATP release from cultured cortical astrocytes (IC₅₀: 142 μM), impacting neuroglial signaling essential for neuronal survival. It also attenuates AngII-induced M1 macrophage polarization via the Cx43/NF-κB pathway (Wu et al., 2020). The compound is water-soluble (≥58 mg/mL), stable at -20°C, and offered by APExBIO as product B4919 for advanced neuroinflammation and immune modulation research.

Biological Rationale

Connexin 43 (Cx43) is a transmembrane protein forming both gap junction channels and hemichannels. Cx43 hemichannels mediate paracrine signaling by releasing small molecules such as ATP, glutamate, and NAD+ (APExBIO). Dysregulation of Cx43 hemichannel activity is implicated in neuroinflammation, neuronal injury, and immune cell activation. In stroke and ischemia/reperfusion (I/R) injury, aberrant hemichannel opening exacerbates excitotoxicity and neurodegeneration (Gap19: Selective Connexin 43 Hemichannel Blocker for Neuroprotection). Conventional pharmacological agents lack selectivity, often inhibiting both gap junctions and hemichannels, which can disrupt essential intercellular communication. Gap19 was designed to precisely target the Cx43 hemichannel pore, preserving gap junctional coupling while preventing pathological ATP and glutamate release.

Mechanism of Action of Gap19

Gap19 is a short, synthetic peptide corresponding to the cytoplasmic loop domain of Cx43. It specifically blocks Cx43 hemichannels by interfering with the cytoplasmic interaction between the Cx43 cytoplasmic loop and C-terminal domain, a critical step for hemichannel gating (Wu et al., 2020). Importantly, Gap19 does not affect Cx43 gap junction channels, as its binding site is functionally exposed only in non-junctional hemichannels. This selectivity is essential for dissecting the distinct roles of Cx43-mediated intercellular versus extracellular signaling (Gap19: Precision Modulation...; this article details new neuroimmune findings not covered there).

In immune cells, Gap19 inhibits the Cx43/NF-κB pathway, thereby attenuating the polarization of macrophages to the pro-inflammatory M1 phenotype. In astrocytes, it blocks ATP release, reducing excitotoxic signaling and promoting neuronal survival. TAT-conjugated Gap19 variants enable systemic delivery and blood-brain barrier penetration, expanding in vivo applications (Advancing Stroke and Neuroinflammation Research...; this article updates mechanistic translational details beyond that review).

Evidence & Benchmarks

• Gap19 inhibits Cx43 hemichannels with an IC₅₀ of approximately 50 μM in vitro (APExBIO product page).
• Gap19 blocks ATP release from cultured cortical astrocytes in a dose-dependent manner (IC₅₀: 142 μM) (APExBIO).
• In a mouse model of middle cerebral artery occlusion (MCAO), intracerebroventricular administration of Gap19 at 300 μg/kg reduced infarct volume and improved neurological scores (APExBIO).
• TAT-Gap19 (25 mg/kg, intraperitoneally, 4 h post-reperfusion) provides neuroprotection and downregulates JAK2/STAT3 activation in cerebral ischemia models (APExBIO).
• Gap19 suppresses AngII-induced M1 polarization in RAW264.7 macrophages by inhibiting Cx43 hemichannel-mediated NF-κB activation (Wu et al., 2020).
• Gap19 is highly water-soluble (≥58.07 mg/mL) and DMSO-soluble (≥26.55 mg/mL), but insoluble in ethanol (APExBIO).
• Gap19 is stable at -20°C for long-term storage; solutions are for short-term use only (APExBIO).

Applications, Limits & Misconceptions

Gap19 enables specific interrogation of Cx43 hemichannel function in neuroglial and immune systems. Its applications include:

• Neuroprotection studies in models of stroke and cerebral ischemia/reperfusion injury.
• Investigation of ATP-dependent neuroglial signaling and excitotoxicity in vitro.
• Modulation of immune cell function, particularly macrophage polarization, via the Cx43/NF-κB axis (Wu et al., 2020).
• Dissection of neuroimmune crosstalk in inflammation and neurodegeneration (Gap19’s precise inhibition…; this article provides newer quantitative benchmarks).

Common Pitfalls or Misconceptions

• Gap19 does not inhibit gap junction channels: It is selective for hemichannels; gap junctional communication remains intact (APExBIO).
• Not active on non-Cx43 connexins: Gap19 is ineffective against hemichannels formed by other connexin isoforms.
• Limited ethanol solubility: Gap19 is insoluble in ethanol; use water or DMSO for reconstitution.
• Short-term solution stability: Reconstituted solutions are stable only for short durations at 4°C; repeated freeze-thaw cycles are discouraged.
• In vivo delivery requires optimization: Blood-brain barrier penetration is inefficient for unconjugated peptide—TAT-conjugation or direct CNS delivery is recommended for systemic studies.

Workflow Integration & Parameters

Gap19 (SKU B4919) is supplied by APExBIO as a lyophilized solid with a molecular weight of 1161.45 Da (C₅₅H₉₆N₁₄O₁₃). For in vitro studies, dissolve at ≥58 mg/mL in water or ≥26.5 mg/mL in DMSO. For animal studies, recommended dosing includes 300 μg/kg (intracerebroventricular) or 25 mg/kg (intraperitoneal, TAT-conjugated). Solutions should be prepared fresh or stored at -20°C for short-term use. Benchmark protocols for ATP release inhibition in astrocytes and neuroprotection in MCAO models are available from APExBIO’s Gap19 product page.

For scenario-driven guidance on cell-based assays and immune modulation, see Gap19 (SKU B4919): Reliable Cx43 Hemichannel Inhibition; this article provides updated application boundaries and troubleshooting tips.

Conclusion & Outlook

Gap19 has established itself as a highly selective and potent Cx43 hemichannel inhibitor peptide, enabling precise modulation of neuroglial and immune signaling. Its robust solubility, reproducible benchmarks, and translational potential position it as an essential reagent for stroke, neuroinflammation, and immune crosstalk research. As new delivery methods and conjugates emerge, Gap19 is poised to further advance our understanding of connexin biology and therapeutic intervention strategies in CNS and immune disorders.